Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.
作者信息
Doolittle Nancy D, Dósa Edit, Fu Rongwei, Muldoon Leslie L, Maron Leeza M, Lubow Meredith A, Tyson Rose Marie, Lacy Cynthia A, Kraemer Dale F, Butler Robert W, Neuwelt Edward A
机构信息
Oregon Health and Science University, Portland, OR.
出版信息
J Clin Oncol. 2013 Nov 1;31(31):4026-7. doi: 10.1200/JCO.2013.52.7747. Epub 2013 Oct 7.
Abstract
摘要
相似文献
1
Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.
J Clin Oncol. 2013 Nov 1;31(31):4026-7. doi: 10.1200/JCO.2013.52.7747. Epub 2013 Oct 7.
2
Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
Neuro Oncol. 2012 Jan;14(1):101-8. doi: 10.1093/neuonc/nor186. Epub 2011 Oct 19.
3
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.
Ann Neurol. 2010 Feb;67(2):182-9. doi: 10.1002/ana.21824.
4
The long term effects of chemotherapy on the central nervous system.
J Biol. 2006;5(7):21. doi: 10.1186/jbiol51.
5
Clearing the air: a review of our current understanding of "chemo fog".
Curr Oncol Rep. 2013 Jun;15(3):260-9. doi: 10.1007/s11912-013-0307-7.
6
Cognitive functions in survivors of primary central nervous system lymphoma.
Neurology. 2004 Feb 24;62(4):548-55. doi: 10.1212/01.wnl.0000109673.75316.d8.
7
Intra-CSF rituximab for lymhomatous meningitis.
J Clin Oncol. 2007 Oct 1;25(28):4508-9; author reply 4509-11. doi: 10.1200/JCO.2007.12.6797.
8
Low neuropsychologic performance among adult cancer survivors treated with chemotherapy.
Curr Neurol Neurosci Rep. 2003 May;3(3):215-22. doi: 10.1007/s11910-003-0081-2.
9
Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.
J Clin Oncol. 2002 Jan 15;20(2):485-93. doi: 10.1200/JCO.2002.20.2.485.
10
Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
Clin Transl Oncol. 2007 Jul;9(7):465-7. doi: 10.1007/s12094-007-0086-4.
引用本文的文献
1
Neurotoxic effects of the chemotherapeutic drug "methotrexate": a literature review.
Ann Med Surg (Lond). 2024 Dec 23;87(3):1394-1405. doi: 10.1097/MS9.0000000000002863. eCollection 2025 Mar.
2
Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.
Ann Lymphoma. 2021 Sep;5:23. doi: 10.21037/aol-21-20.
3
Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.
Ann Lymphoma. 2021 Mar;5. doi: 10.21037/aol-20-47.
4
Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses.
Proc Natl Acad Sci U S A. 2021 May 4;118(18). doi: 10.1073/pnas.2021915118.
5
Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort.
Front Oncol. 2021 Jan 20;10:543648. doi: 10.3389/fonc.2020.543648. eCollection 2020.
6
Drug Delivery Technology to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience.
Pharmaceutics. 2019 May 27;11(5):248. doi: 10.3390/pharmaceutics11050248.
7
Boron delivery agents for neutron capture therapy of cancer.
Cancer Commun (Lond). 2018 Jun 19;38(1):35. doi: 10.1186/s40880-018-0299-7.
8
Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.
Fluids Barriers CNS. 2017 Jun 2;14(1):16. doi: 10.1186/s12987-017-0064-3.
9
NIH workshop report on the trans-agency blood-brain interface workshop 2016: exploring key challenges and opportunities associated with the blood, brain and their interface.
Fluids Barriers CNS. 2017 May 1;14(1):12. doi: 10.1186/s12987-017-0061-6.
10
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
J Neurooncol. 2017 Jan;131(2):293-300. doi: 10.1007/s11060-016-2293-8. Epub 2016 Oct 17.
本文引用的文献
1
Flying solo: chemotherapy without radiation for primary CNS lymphoma.
J Clin Oncol. 2013 Sep 1;31(25):3051-3. doi: 10.1200/JCO.2013.48.9138. Epub 2013 May 28.
2
Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.
Neurology. 2013 Jul 2;81(1):84-92. doi: 10.1212/WNL.0b013e318297eeba. Epub 2013 May 17.
3
The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.
J Neurooncol. 2012 Jun;108(2):285-90. doi: 10.1007/s11060-012-0807-6. Epub 2012 Feb 17.
4
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
J Clin Oncol. 2009 Jul 20;27(21):3503-9. doi: 10.1200/JCO.2008.19.3789. Epub 2009 May 18.
5
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research.
J Clin Oncol. 2007 Jun 10;25(17):2455-63. doi: 10.1200/JCO.2006.08.1604. Epub 2007 May 7.
6
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.
Ann Oncol. 2007 Jul;18(7):1145-51. doi: 10.1093/annonc/mdl464. Epub 2007 Feb 6.
7
Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.
J Clin Oncol. 2006 Mar 10;24(8):1305-9. doi: 10.1200/JCO.2005.04.6086.
8
Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function.
J Clin Oncol. 1991 Sep;9(9):1580-90. doi: 10.1200/JCO.1991.9.9.1580.
Zotero 插件